Bristol-Myers Squibb (BMY) Announces Acquisition of RayzeBio (RYZB) for $62.50 Per Share, $4.1 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023 6:59 AM ESTÂ Transaction Brings RayzeBios Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibbs Leading Oncology Franchise
Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types
Gains Robust IND Engine and State-of-the-Art Radiopharmaceutical Manufacturing Capabilities
PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ:... More
